Demographic summary of all cystic fibrosis patients dosed in the European and US trials (mean (SD))
| Arikace 70 mg (n=7) | Arikace 140 mg (n=5) | Arikace 280 mg (n=21) | Arikace 560 mg (n=36) | Placebo (n=36) | |
|---|---|---|---|---|---|
| Age, years | 33.1 (9.7) | 35.4 (6.0) | 16.0 (5.3) | 23.0 (12.6) | 20.3 (7.7) |
| Females, n (%) | 6 (85.7) | 1 (20.0) | 16 (76.2) | 15 (41.7) | 20 (55.6) |
| FEV1 (L) | 1.87 (0.41) | 2.88 (0.40) | 2.022 (0.79) | 2.19 (0.87) | 2.13 (0.70) |
| FEV1 (% predicted) | 59.29 (12.60) | 70.40 (10.09) | 66.40 (20.00) | 66.39 (17.44) | 67.86 (19.36) |
| FEF25–75% (L/s) | 0.96 (0.52) | 1.91 (0.92) | 1.60 (0.90) | 1.692 (0.933) | 1.53 (0.87) |
| FVC (L) | 3.00 (0.60) | 4.25 (0.42) | 2.80 (1.10) | 3.01 (1.20) | 3.08 (1.09) |
| BMI (kg/m2) | 22.97 (1.57) | 26.33 (3.19) | 18.06 (2.29) | 20.38 (4.06) | 19.90 (3.46) |
BMI, body mass index; FVC, forced vital capacity; FEF, forced expiratory flow.